Erin A. Larkins

发表

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

Jiang Liu, Jielin Sun, Reena Philip, 2021, Clinical Cancer Research.

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions

Jiang Liu, Reena Philip, R. Pazdur, 2020, Clinical Cancer Research.

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma

Jiang Liu, Martha Donoghue, R. Pazdur, 2021, Clinical Cancer Research.

U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.

P. Keegan, R. Pazdur, G. Blumenthal, 2015, The oncologist.

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy

K. Goldberg, P. Keegan, Amy McKee, 2017, The oncologist.

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.

R. Pazdur, Shenghui Tang, J. Beaver, 2021 .

FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.

P. Keegan, R. Pazdur, G. Blumenthal, 2018, Seminars in oncology.

FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.

K. Goldberg, R. Pazdur, M. Theoret, 2021, The oncologist.